New drugs for peripheral T-cell lymphomas

Haematologica Reports

Volumn 2, Issue 13, 2006, Pages 42-45

  Cheson, B D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; FLUDARABINE; FORODESINE; GALLIUM NITRATE; GOSSYPOL; ISOSORBIDE; LENALIDOMIDE; NELARABINE; NEW DRUG; OBATOCLAX; OBLIMERSEN; PENTOSTATIN; RAPAMYCIN; RITUXIMAB; SGN 30; TEMSIROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VORINOSTAT;

ARTICLE; B CELL LYMPHOMA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RECURRENT CANCER; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 34250019154     PISSN: 18249337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588-1593.
2. Kong LR, Samuelson E, Rosen ST, et al. 2-chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma 1997;26:89-97.
3. Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996;87:906-11.
4. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 2005;106:4253-60.
5. Berg SL, Ernst TJ, Keating MJ, et al. Phase II study of nelarabine (compound 506U78) in children and youngs adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005;23:3376-82.
6. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8.
7. Heaney M, O'Connor OA, Richon V, et al. Clinical experience with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pretreated patients with hematological malignancies. Proc ASCO 2033;22:577 (abstr 2321).
8. Olsen E, Kim YH, Kuzel T, et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is cliinically active in advanced cutaneous T-cell lymphomas (CTCL): results of a phase IIb trial. J Clin Oncol 2006;24:422s (abstr 7500).
9. Talpur R, Apisarnthanarax N, Ward S, et al. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 2002;43:121-6.
10. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-4.
11. Ansell S, Byrd J, Horwitz S, et al. Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL). Blood 2003;102:181a (abstr #632).
12. Bartlett NL, Bernstein SH, Leonard JP, et al. Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patietns with refractory or recurrent CD30+ hematologic malignancies. Blood 2003;102:647a (abstr #2390).
13. Schwänen C, Karakas T, Begmann L. Bendamustine in the treatment of low-grade non-Hodgkin's lymphomas. Onkologie 2000;23:318-24.
14. Kath R, Blumenstengel K, Fricke HJ, et al: Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001;127:48-54.
15. Rummel MJ, Mitrou PS, Hoelzer D: Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Sem Oncol 2002;29:27-32.
16. Rummel MJ, Kim SZ, Chow KU, et al. Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas. Blood 2003;102:104a (abstr 353).
17. Bremer K: High rates of long-lasting remissions after 5-day bendamustine chemothereapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res ClinOncol 2002;128:603-9.
18. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1285-9.
19. Rummel MJ, Al-Batran S, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005,23:3383-9.
20. Friedberg JW, Cohen P, Cheson BD, et al. Bendamustine HCL (TREANDA) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin's lymphoma (NHL): Results from a phase II multicenter single-agent study. Blood 2005,106:70a (abstr 229).
21. Warrell RP, Jr., Coonley CJ, Straus DJ, et al. Treatment of patients with advanced malignant lymphoma using gallium nitrate administration as a seven-day continuous infusion. Cancer 1983;51:1982-7.
22. Keller J, Bartolucci A, Carpenter JT, Jr., et al. Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:1221-3.
23. Weick JK, Stephens RL, Baker LH, et al. Gallium nitrate in malignant lymphoma: A Southwest Oncology Group study. Cancer Treat Rep 1983;7:823-5.
24. Huang Z, Higgins B, Foss F. Activity of gallium nitrate in refractory T-cell lymphoma. Clin Lymphoma 2005;6:43-5.
25. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 2005;352:2487-98.
26. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
27. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
28. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in relapsed or refractory mantrle cell lymphoma (MCL): results of the PINNACLE study. J Clin Oncol 24:425s (abstr 7513), 2006
29. Blum KA, Johnson JL, Niedzwiecki D, et al: A phase II study of bortezomib in relapsed Hodgkin's lymphoma: preliminary results of CALGB 50206. J Clin Oncol 2006;24:440s (abstr 7576).
30. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995;60:264-70.
31. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000;103:253-62.
32. Witzig T, Geyer S, Ghobrial I, et al. Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Ann Oncol 2005;16:19 (abstr 095).
33. Ansell SM, Geyer SM, Kurtin PJ, et al: Anti-tumor activity of mTOR inhibitor temsirolimus for relapsedmantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2006;24:430s (abstr 7532).
34. Younes A, Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21:3526-34.
35. O'Brien SM, Cunningham CC, BGolenkov AK, et al. Phase I to II mujlticenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697-702.
36. Kirkwood JM, Bedikian AY, Millward MJ, et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). J Clin Oncol 2005;23:711s (abstr 7506).
37. Leonard J, Hainsworth J, Bernstein S, et al. Genasense (Oblimerson sodium, G3139) is active and well-tolerated both alone and with R-CHOP in mantle cell lymphoma. Blood 2003;102:abstr 490.
38. James DF, Castro JE, LoriaO, et al. AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients (pts) with high risk features: Preliminary results from an ongoing phase I trial. J Clin Oncol 2006;24:362s (abstr 6605).
39. O'Brien S, Kipps T, Faderl S, et al. A phase I trial of the small molecule pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 233ks to patients with previously treated chronic lymphocytic leukemia (CLL). Blood in press, 2005.
40. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with APO2L/TRAIL. Curr Opinion Pharmacol 2004; 4:333-9.
41. Grinblatt DL, Johnson J, Niedzwiecki D, et al. Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL). Blood 2004;104:897-898a.
42. Chanan-Khan AA, Miller KC, Dimiceli L, et al. Results of a phase II study of lenalidomide (L) (Revlimid) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2005;106:abstr 448.